(HealthDay)—Fragmin (dalteparin sodium) injection has been granted the first approval for subcutaneous use in preventing recurrence of symptomatic venous thromboembolism (VTE) in children aged 1 month or older, the U.S. Food and Drug Administration announced. Fragmin has been approved for use in adults since 1994. Approval in children was based on a trial of 38 pediatric patients with symptomatic deep […]

Continue reading »